Long-term effects of finasteride in patients with benign prostatic hyperplasia: A double-blind, placebo-controlled, multicenter study

Urology

Volumn 51, Issue 5, 1998, Pages 677-686

  Marberger, Michael J ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLADDER OBSTRUCTION; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; IMPOTENCE; LIBIDO; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; URINE FLOW RATE; URINE RETENTION;

AGED; ANALYSIS OF VARIANCE; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FINASTERIDE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PLACEBOS; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATIC HYPERPLASIA; TESTOSTERONE 5-ALPHA-REDUCTASE; URINARY RETENTION; URINATION;

EID: 0031744756     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00094-6     Document Type: Article

References (18)

1. Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, Lieber MM. The prevalence of prostatism a population-based survey of urinary symptoms . J Urol. 150:1993;85-89.
2. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 335:1996;533-539.
3. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 327:1992;1185-1191.
4. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate. 22:1993;291-299.
5. Andersen JT, Ekman P, Wolf H, Beisland HO, Johanssen JE, Kontturi M, Lehtonen T, Tveter K. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study . Urology. 46:1995;631-637.
6. Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perrault J-P, Afridi SK, Elhilali MM. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia results of a 2-year randomized controlled trial (the PROSPECT study) . Can Med Assoc J. 155:1996;1251-1259.
7. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride meta-analysis of randomized clinical trials . Urology. 48:1996;398-405.
8. Gormley GJ. Finasteride a clinical review . Biomed Pharmacother. 49:1995;319-324.
9. Bolognese JA, Kozloff RC, Kunitz SC, Grino PB, Patrick DL, Stoner E. Validation of a symptoms questionnaire for benign prostatic hyperplasia. Prostate. 21:1992;247-254.
10. Andersen JT, Nickel JC, Marshall VR, Schulman CC, Boyle P. Finasteride significantly reduces acute urinary retention and the need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology. 49:1997;839-845.
11. Moore E, Bracken B, Bremner W, Geller J, Imperato-McGinley J, McConnell J, Roy J, Tenover L, Vaughan D, Pappas F, et al. Proscar® 5-year experience . Eur Urol. 28:1995;304-309.
12. Barry MJ, Cockett ATK, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol. 150:1993;351-358.
13. Jensen KME, Bruskewitz RC, Iversen P, Madsen PO. Significance of prostate weight in prostatism. Urol Int. 38:1983;173-178.
14. Abrams PH, Feneley RCL. The significance of symptoms associated with bladder outflow obstruction. Urol Int. 33:1978;171-174.
15. Girman CJ, Jacobson SJ, Guess HA, Oesterling JE, Chute CG, Panser LA, Lieber MM. Natural history of prostatism relationship among symptoms, prostate volume and peak urinary flow rate . J Urol. 153:1995;1510-1515.
16. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM. Serum prostate-specific antigen in a community-based population of healthy men Establishment of age-specific reference ranges . JAMA. 270:1993;860-864.
17. Jacobsen SJ, Jacobsen DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Lieber MM. Natural history of prostatism risk factors for urinary retention . J Urol. 158:1997;481-487.
18. Malone PR, Cook A, Edmondson R, Gill MW, Shearer J. Prostatectomy patients' perception and long-term follow up . Br J Urol. 61:1988;234-238.